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Asymmetric Redundancy in CD4 Silencer Function
David D. Duncan, Matthew Adlam, CD41CD82 or CD42CD81 populations (Kisielow et al.,
1988b; Sha et al., 1988a, 1988b; Teh et al., 1988; Kayeand Gerald Siu
Department of Microbiology et al., 1989). This down-regulation is an important event
in the final maturation of the T cell, as it insures thatColumbia University
College of Physicians and Surgeons CD4 is expressed only in T cells that are restricted to
MHC class II, and CD8 is expressed only in T cells thatNew York, New York 10032
are restricted to MHC class I. Using nuclear run-ons, it
has been determined that the control of expression of
CD4 during each stage of T cell development, includingSummary
the final down-regulation, is at the level of the initiation
of transcription (Siu et al., 1994; Takahama and Singer,We and others have defined a transcriptional silencer
1992). Since this process is linked closely to each stagecritical for the proper expression of the CD4 gene at
of T cell development, an analysis of the factors thatall stages of T cell development. In this report, we
initiate or inhibit expression of the CD4 gene will helpuse biochemical techniques to identify three different
delineate the molecular mechanisms of T cell develop-factor-binding sites within the CD4 silencer, denoted
ment and selection and thus we feel that this is a goodsites I, II, and III. Using transgenic analyses, we deter-
model system for studying these events.mine that although all three factor-binding sites are
Much work has been conducted to study CD4 expres-important for silencer activity, there is significant re-
sion control (for review see Benoist and Mathis, 1994).dundancy in that the presence of either site II alone,
We and others have characterized the promoter regionor the combination of sites I and III permits silencer
and two enhancers in the CD4 locus using transientfunction. Thus, our data indicate that the mechanism
transfection assays (Siu et al., 1992; Sawada and Litt-of function of the CD4 silencer is extremely complex.
man, 1991; Wurster et al., 1994; Duncan et al., 1995).Further biochemical analyses indicate that the factor
Using transgenic mice, we and others have identified abinding to site II has the same sequence specificity
developmental stage±specific transcriptional silencer inas a factor binding to an E box site in the CD4 en-
the first intron of the CD4 gene (Siu et al., 1994; Sawadahancer; thus, a member of the bHLH factor family may
et al., 1994). The CD4 silencer is the critical element thatbe important in mediating silencer function.
limits expression of the CD4 gene to the appropriate
cell types; thus, the factors that bind to the silencerIntroduction
and control its function must be linked to the selection
processes important in T cell development. To studyCD4 is an important molecule in both T cell antigen
how this silencer functions, we have characterized therecognition and in thymic development (Littman, 1987;
factors that bind to the silencer region. We have identi-Parnes, 1989; Swain, 1983; Perlmutter et al., 1988). CD4
fied three major factor-binding sites within the silenceris expressed on all T cells that recognize antigen bound
region, denoted sites I, II, and III. Site II contains a con-to major histocompatibilitycomplex (MHC) class II mole-
sensus E box, and our biochemical data indicate thatcules, a subclass of T cells that consists primarily of
the factorbinding this sitehas similar sequence specific-helper T cells (Th cells) (Swain, 1983). CD8, a similar
ity to an E box±binding factor. We have generated adifferentiation molecule, is expressed on the surface of
panel of silencer deletion mutants and tested each inall T cells that recognize antigen bound to the MHC
transgenic mice. We determined that the deletion of anyclass I molecule, a subclass of T cells that consists
single site does not affect silencer function, whereasprimarily of cytotoxic T cells (Swain, 1983). In addition
the deletion of the E box site in combination with anyto its role in antigen recognition, CD4 is an important
one of the remaining sites results in complete abrogationmolecule in T cell development. CD4 is first expressed
of silencing. These results indicate that the CD4 silencerat low levels in early pluripotent hematopoietic stem
is composed of functionally redundant elements. How-cells (Spangrude et al., 1988). T cell precursors that first
ever, the redundancy is asymmetric in that the factorsarrive in the thymus from the bone marrow maintain
that bind to the E box site and the factors that bind tothis low level of expression (CD4loCD82 T cell antigen
sites I and III are functionally equivalent in silencingreceptor [TCR]; Wu et al., 1991). CD4 expression is then
potential.down-regulated, resulting in the CD42CD82 thymocyte.
These cells subsequently express low levels of CD8,
followed by increasing levels of both CD4 and CD8, and
Resultsthe TCR.The resulting CD41CD81 thymocyte population
then undergoes the TCR-mediated positive and nega-
The CD4 Silencer Has Three Factor-Binding Sitestive selection processes, all of which require the proper
To characterize the factors that bind to the CD4 silencerexpression of CD4 and CD8 (Fowlkes and Pardoll, 1989;
and mediate its function, we first conducted DNAse foot-von Boehmer, 1994; Nossal, 1994; Kisielow et al., 1988a;
printing analyses on the minimal CD4 silencer regionKruisbeek et al., 1985; Berg et al., 1989; Cosgrove et
to identify all of the potential factor-binding sites. Theal., 1991; Grusby et al., 1991). The survivors will then
down-regulate either CD4 or CD8, leading to the mature minimal silencer region has been defined as a 434 bp
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footprint over site I using nuclear extracts purified from
the L929 fibroblast (Figure 2A) that is qualitatively differ-
ent from the footprint observed using the T cell nuclear
extracts. The footprint detected inL929 extracts encom-
passes a 39 bp region that contains the smaller D10
and L3 site I footprint. The site II region is an 18 bp
region that can be detected using both the D10 and L3
nuclearextracts, butnot theB cell, L929, orHeLa nuclear
extracts (Figure 2B). Although we can detect a faint
footprint in the L929 extract on the negative strand, we
cannot detect a footprint in the same position on the
positive strand (Figure 2B; data not shown). Thus, as
for site I, the presence of a footprint over site II does
not appear to correlate completely to cell types thatFigure 1. Sequence of the Minimal CD4 Silencer Region
either express or do not express CD4. The site III regionFootprinted sites are indicated by boxes. Fok I (F) and Bsp1286 (B)
has a very complex footprint seen best on the negativecleavage sites used to generate restriction enzyme fragments for
or noncoding strand (Figure 2C). Nuclear extracts puri-probes for DNase footprinting are indicated. The consensus E box
in site II is indicated in bold. fied from the D10 CD41 Th cell and the L929 fibroblast
protect a large 45 bp region. The HeLa epithelial cell
line also protects a large region, whereas the L3 CD81
SacI±XbaI fragment located in the first intron (Figure 1; cytotoxic T cell, and the P3X63 and Namalwa B cell
Sawada et al., 1994; Siu et al., 1994; see below). To nuclear extracts protect a much smaller 25 bp region.
determine whether specificity of silencer function iscon- The B cell nuclear extracts, in particular, appear to pro-
veyed by cell type±specific expression of a DNA-binding tect a very small region surrounding a hypersensitive site
factor, we isolated nuclear extracts from a panel of dif- (Figure 2C). The nature of these differences is unclear,
ferent T and B cells as well as nonlymphoid cells (see although it may indicate that different nuclear factors
Experimental Procedures). As can be seen in Figures 1 are binding to site III in these different cell types.
and 2, we can identify three footprinted sites in the CD4 To confirm that nuclear factors bind to the silencer
silencer. The firstsite, site I, encompassesa 15 bp region within the footprinted regions, we generated oligonucle-
and is present in both the D10 CD41 CD82 Th clone and otide probes that contain each of the footprinted sites
the L3 CD42 CD81 cytotoxic T clone, but not in the and used them in electrophoretic mobility shift assay
P3X63 orNamalwa Bcell lymphomas or the HeLaepithe- (EMSA) analyses with the D10 CD41CD82 and L3
CD42CD81 nuclear extracts. As can be seen in Figurelial cell (Figure 2A). Interestingly, we can detect a broad
Figure 2. DNase Footprinting Analysis of the CD4 Silencer
(A) Site I.
(B) Site II.
(C) Site III.
DNase footprinting on positive (plus) and negative (minus) strands are indicated. Nuclear extracts used were purified from the CD4 SP Th
clone D10 (CD4SP), the CD8 SP cytotoxic T cell clone L3 (CD8 SP), the murine (M) plasmacytoma P3X63Ag8 (B cell M), the human (H) B cell
lymphoma Namalwa (B cell H), the murine fibroblast L929 (Fibroblast M), and HeLa. Free probe digestions are indicated. Multiple lanes in
some footprints show different titrations of dilutions of DNase.
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Figure 3. EMSA Analyses of the Factor-Binding Sites in the CD4 Silencer Region
(A) Site I. L3 or D10 (D) nuclear extracts were incubated with radioactive site I probe either alone, or radioactive site I probe with excess
nonradioactive site I (lanes labeled I) or nonspecific linker (lanes labeled L) oligonucleotides as described in Experimental Procedures.
(B) Site II. D10 nuclear extracts were incubated with radioactive site II probe either alone or with radioactive site II probe with excess
nonradioactive site II (lanes labeled II) or nonspecific oligonucleotide (lanes labeled L).
(C) Site III. D10 nuclear extracts were incubated with radioactive site III probe either alone, or with radioactive site III probe with excess
nonradioactive site III oligonucleotide encompassing the complete footprinted region (lanes labeled III/IV), the site III recognition site as
identified by o-phenanthroline copper footprinting (lanes labeled III), or nonspecific competitor (lanes labeled L). For all figures, arrows indicate
specific complexes; free probe is indicated. Sequences of the probes utilized for each site are boxed in Figure 1.
3A, we can detect two complexes using the site I probe not shown). This complex can only be detected when
T cell extracts are used, which is consistent with theand D10 nuclear extract; this interaction is specific in
that we can inhibit complex formation by adding 100- DNAse footprinting data shown above (data not shown).
Using site III as a probe and D10 nuclear extracts, weand 300-fold molar excess of nonradioactive site Iprobe,
whereas the addition of similar amounts of nonspecific can detect at least one major complex (Figure 3C). In
addition, we can often detect at least one minor bandcompetitor have little effect. We can detect two com-
plexes using the site I probe and nuclear extracts puri- in some experiments (data not shown). Both of these
complexes can be competed successfully with two dif-fied from P3X63, Namalwa, L929, and HeLa extracts;
these complexes have similar mobilities to those seen ferent oligonucleotides containing the site III region
(competitors III/IV and III; Figure 3C), but not nonspecificwith the D10 extracts and thus may represent the same
factors binding to these sites (data not shown). These oligonucleotides; we obtained similar results with all of
the extracts from the other cell types mentioned abovedata are inconsistent with the DNAse footprinting data
shown above, where we were unable todetect footprints (Figure 3C; data not shown). We thus conclude that
both T cell±specific and ubiquitously expressed nuclearin B cell and HeLa extracts. This difference may be the
result of the differential sensitivities of the two tech- factors are binding to the CD4 silencer at the footprinted
sites and may be contributing to its function. To confirmniques used; DNAse footprinting requires high levels of
nuclear factor in the extract, whereas EMSA analyses that we have identified all of the factor-binding sites
within the CD4 silencer region, we utilized restrictionare very sensitive even to small amounts of nuclear
factor. Thus, our failure to detect footprints in the B cell enzyme fragments that contained portions of the CD4
silencer region in EMSA analyses (data not shown) usingextracts may reflect lower levels of expression of the
factor in these cell types. Using the L3 nuclear extract, the panel of nuclear extracts described above. In these
experiments, we cannot detect the presence of addi-we can detect three complexes; one complex is similar
in mobility to the major complex seen with the other cell tional complexes other than those representing the sites
I-, II-, and III-binding factors (data not shown).types, whereas the other two have different mobilities.
The nature of these differences or their significance is
unclear.
We can detect a single complex with the site II probe The Site II-Binding Factor
Sequence analysis of the site II region revealed a con-using D10 or L3 nuclear extracts; 100- and 300-fold
molar excesses of the nonradioactive site II probe inhibit sensus E box recognition site (see Figure 1, bold). Previ-
ous work has shown that an E12-HEB heterodimer bindscomplex formation, whereas similar molar amounts of
nonspecific competitor have little effect (Figure 3B; data to the proximal CD4 enhancer at a functionally relevant
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slow mobility complex represents the E12-HEB hetero-
dimer binding to the 59 E box site (referred to as CD4-
3C). The identities of the other complexes are unknown;
using mutational and EMSA analyses, however, it was
determined that fast mobility complex binds to the 39 E
box site (Sawada and Littman, 1993). We can inhibit
formation of all three complexes using nonradioactive
CD4 enhancer but not nonspecific oligonucleotides as
competitors, indicating that the binding of all three com-
plexes to the CD4 enhancer probe is specific (Figure 4,
lanes 2, 3, 6, and 7). However, using the CD4 silencer
site II probe as nonradioactive competitor, we can inhibit
formation of the fast mobility complex, but not the other
two complexes (Figure 4, lanes 4 and 5). These data
indicate that the factor that binds to the CD4 enhancer
at the 39 E box site has a similar sequence specificity
as the factor binding the CD4 silencer at site II, which
Figure 4. The Site II-BindingFactor Has a Sequence SpecificitySim-
supports the theory that these two factors are encodedilar to a CD4 Enhancer-Binding Protein
by the same gene (see below).D10 nuclear extracts were incubated with radioactive CD4 enhancer
E box (CD4-3C; see text for details) probe (lanes 1±7) or with CD4
silencer site II probe (lanes 9±15). D10 nuclear extracts were incu-
The Site III Factor-Binding Sitebated with radioactive probe only (lanes 1 and 9) or with each re-
spective radioactive probe and excess nonradioactive CD4-3 (lanes DNAse footprinting analysis on the site III region re-
2, 3, 10, and 11), site II (lanes 4, 5, 12, and 13), or nonspecific vealed a broad footprint, spanning 25±45 bp. To deter-
competitor (lanes 6, 7, 14, and 15). For the EMSAs with the E box mine the precise factor-binding site of the major site
probe (lanes 1±7), the arrow indicates the fast mobility complex
III-binding factor identified above, we conducted o-whose formation is inhibited by the addition of the site II probe
phenanthroline copper footprinting on the major site III-(lanes 4 and 5). The E12/HEB-containing complex and free probe
binding complex. As can be seen in Figure 5, the siteare indicated.
III-binding complex protects a 16 bp sequence within
the site III region. This sequence contains of two 5 bp
direct repeats (CTGTG) separated by a 6 bp spacer, andsite and thus may play a role in CD4 transcription (Sa-
does not match the consensus recognition site of anywada and Littman, 1993). To determine whether the site
known transcription factor. From these data, we con-II-binding factor has a sequence specificity similar to a
clude that the nuclear factor that forms the major sitebHLH transcription factor, we conducted EMSA compe-
III-binding complex binds at this site.tition analyses with an oligonucleotide that contained
the two E box sites from the CD4 proximal enhancer
(the CD4-3 probe). As can be seen in Figure 4 (lanes Transgenic Reporter Constructs
8±15), we can successfully inhibit formation of the site
To determine which of the factor-binding sites are im-
II-binding complex using molar excesses of nonradioac-
portant in silencer function, we have utilizeda transgenic
tive oligonucleotide containing these E box sites (com- reporter system. Although the CD4 silencer has been
pare lanes 10 and 11 with lane 9). The extent of inhibition reported to function in transient transfection analyses
of complex formation is roughly equivalent to the inhibi- with established cell lines, we have been unable to ob-
tion seen using nonradioactive site II oligonucleotide at tain significant silencer function using these ap-
similar molar excesses (Figure 4, compare lanes 12 and proaches. In addition, use of transgenic mice enables
13 with lanes 10 and 11). These data indicate that at us to determine silencer function in a wide variety of cell
least one of the two E box sites in the CD4 proximal types. In our original experiments, we identified seven
enhancer probe is capable of inhibiting complex forma- DNAse hypersensitive sites in the 59 flanking region of
tion between the site II probe and its cognate binding the CD4 gene, and utilized large restriction fragments
factor. encompassing each of these sites in our transgenic con-
To determine which of the two sites in the CD4 en- structs (Siu et al., 1994). Because of the size of the
hancer probe was competing with the site II probe, we restriction fragments, we were forced to use l phage
conducted EMSA competitions using the CD4 enhancer and cosmid vectors for cloning our final constructs. As
oligonucleotide as a radioactive probe and the CD4 si- this was too cumbersome to use for our current studies,
lencer site II oligonucleotide as the competitor (Figure we have generated a reporter construct that contains
4; lanes 1±7). The CD4 enhancer probe contains two E all of the known transcriptional control elements in the
box recognition sites; the 59 site is the only site that is 59 region (Figure 6). This construct (pTG) contains the
required for enhancer function in transient transfections minimal CD4 promoter and distal and proximal en-
and is bound by a heterodimer of an E12-like transcrip- hancers, and the human HLA-B7 gene as a marker. We
tion factor and the HEB transcription factor (Sawada chose the HLA-B7 gene as a marker, as its expression
and Littman, 1993). Using D10 nuclear extracts, we can can be detected easily using monoclonal antibodies and
detect the three major complexes using the CD4 en- its expression does not affect the development of the
T cell in the thymus (for full discussion of these issueshancer probe identified previously (Figure 4, lane 1). The
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Figure 6. pTG Series Transgenic Constructs
pTG base vector shown above; shaded and open boxes indicate
enhancer regions (distal, DE; proximal, PE) and promoter, respec-
tively. Silencers are shown below: striped and closed boxes indicate
presence or deletion of factor-binding sites, respectively. Open
boxes indicate flanking sequences within the minimal silencerFigure 5. o-Phenanthroline Copper Footprinting of the Site III
region.Region
Positive-strand (left) and negative-strand o-phenanthroline copper
footprints of the site III-binding complex. Complex-bound and free
constructs, where all six of the lB and cosC transgenicprobe digests are indicated; lines indicate footprinted regions. Se-
mice that inserted the transgenic construct intact ex-quence below indicates minimal site III recognition site as deter-
pressed themarker (Siu et al., 1994). These data indicatemined by o-phenanthroline copper footprints.
that there may be additional transcriptional control ele-
ments in the lB and cosC constructs that are not present
on the pTG construct that are important for determiningsee Siu et al., 1994). Different silencer mutations con-
levels of expression but not specificity (see Discussion).taining either single, double, or triple deletions of the
three footprinted sites were generated, and each mutant
was cloned into the pTG construct (Figure 6). Transgenic
Table 1. Transgenic Lines Generated
mice were generated from each construct, and multiple
Construct Number of Numberfounders were then identified, bred, and analyzed for
transgenic mice expressingmarker gene expression in the CD41 and CD42 compart-
pTGSil 3 2ments (Table 1; Figure 7; data not shown). By Northern
pTG 6 5analysis, marker gene expression is limited to the spleen
pTGSilDI 8 3and the thymus in pTG transgenic mice, which is consis-
pTGSilDII 4 3
tent with previous data indicating that the CD4 promoter pTGSilDIII 6 5
and enhancers are sufficient to limit expression to hema- pTGSilDI/II 8 2
topoietic tissues (data not shown). Interestingly, approx- pTGSilDI/III 5 3
pTGSilDII/III 6 3imately 50% of the transgenic mice generated from the
pTGSilDI/II/III 7 3pTG-based constructs did not express the marker gene
pTGSilMin 8 4in any tissue or cell type (Table 1). This contrasts with
Total 61 33
our previous data using the l and cosmid transgenic
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Figure 7. Marker Expression in Transgenic
Mice
(A) Single deletions do not affect silencer
function. Peripheral T cell populations were
isolated from transgenic mice either from the
spleen (pTGSil, pTG, DIII) or from peripheral
blood (DI, DII) and stained with monoclonal
antibodies to CD4, CD8, and the HLA-B7
marker gene. The CD41CD82 and CD42CD81
population were gated on and analyzed for
HLA-B7 expression.
(B) Specific double deletions abrogate si-
lencer function. Peripheral T cell populations
were isolated from transgenic mice either
from the spleen (DI/III and DII/III) or from pe-
ripheral blood (DI/II, DI/II/II, pTGSilMin) and
stained, and analyzed for HLA-B7 expression
as described above. Solid lines indicatestain-
ing with anti-HLA-B7 antibody, dashed lines
indicate staining with isotype-matched con-
trols. All expressing founders were analyzed
and consistent with those shown. The origin
of the marker negative population in some of
the CD41CD82 populations is unclear. This
population is usually present only in periph-
eral blood analysis and is resolved when
splenocytes are analyzed. Thus, this popula-
tion may be the result of contaminating cells
as a result of imperfect red blood cell lysis.
As can be seen in Figure 7A, mice that are transgenic sites within the silencer such that single deletions of
any one of the three sites do not affect silencer function.with the pTGSil construct containing the unmutated si-
lencer correctly express the marker in the peripheral
CD41CD82 T cells, but not the CD42CD81 T cells. How- The Double Deletions of Either Site I/Site II
or Site II/Site III Are Required toever, the pTG transgenic mice express the marker in
both mature T cell populations (Figure 7A). These data Abrogate Silencer Function
Next, we were interested in determining the extent ofare consistent with previous work, indicating that the
CD4 silencer is responsible for limiting gene expression the functional redundancy of these factor-binding sites.
To do this, we generated transgenic mice with pTG con-to the CD41 T cell classes. Interestingly, we were unable
to detect expression of the marker gene in CD41CD81 structs containing silencers with double-site deletions
or with all three sites deleted (pTGSilDI/II, pTGSilDI/III,thymocytes in any of the pTG-based construct transgenic
mice (data not shown). In addition, transgenic founder pTGSilDII/III, and pTGSilDI/II/III; Table 1; Figure 7B). As
for the single-deletion transgenic mice described above,mice generated from two similar transgenic constructs
also do not express the marker gene in the CD41CD81 multiple founders were generated and peripheral CD41
and CD42 populations analyzed for marker gene expres-thymocyte populations. These data indicate that the
pTG-based constructs lack an important cis-acting tran- sion. Surprisingly, silencer function in mature CD42CD81
T cells is not affected by the double deletion of sites Iscriptional control element that is necessary for gene
expression in double-positive cells in the thymus (see and III (Figure 7B). In addition, we can detect marker
expression on the thymic CD41CD82 T cells, but not onbelow for further discussion).
the thymic CD42CD81 or the immature CD42CD82 T cell
populations (data not shown). These data indicate thatDeletion of Any One of the Three Sites Does
Not Affect Silencer Specificity or Function there is significant functional redundancywithin the CD4
silencer such that site II alone in the context of theTo determine which of the factor-binding sites are im-
portant in silencer function, we generated transgenic silencer can mediate silencer function in mature CD42
T cells. However, the double deletion of site I and sitemice with the pTG constructs with silencers that con-
tained single-site deletion mutations (pTGSilDI, pTGSil- II or site II and site III leads to abrogation of silencer
function; as can be seen in Figure 7B, the pTGSilDI/IIDII, pTGSilDIII). Multiple founders were obtained and
analyzed (Table 1) for marker expression in the mature and pTGSilDII/III founders expressed the marker gene in
both mature CD41CD82 and CD42CD81 T cells. Similarly,T cell populations in spleen. Interestingly, deletion of
any one of the three footprinted sites does not affect the triple deletion (pTGSilDI/II/III) also breaks silencer
function (Figure 7B). From these data, we can draw sev-silencer function; as can be seen inFigure 7A, transgenic
mice that contain these single-deletion silencer con- eral conclusions. First, the factor that binds site II alone
in the context of the silencer is capable of mediatingstructs express the HLA-B7 marker gene only in the
CD41 CD82 and not in the CD42 CD81 T cell populations. silencer function. Second, despite its critical role, its
deletion can be compensated by the presence of bothThese data indicate that there is sufficient functional
redundancy between the three different factor-binding site I and site III and thus, at least for CD42CD81 T
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cells, the factors binding sites I and III are functionally to the RE1/NSRE element in nonexpressing cells, thus
initiating a silencing mechanism that blocks default tran-equivalent to the factor that binds to site II. To determine
whether the three factor-binding sites within the silencer scription of the type II sodium channel and SCG10
genes. Our data indicate that for the CD4 silencer thereare all that is necessary for function, we generated a
minimal silencer construct that contains oligonucleo- is no correlation between the presence or absence of
binding factors and the expression or lack of expressiontides containing only the footprinted sites. However,
mice transgenic with this construct express the marker of the CD4 gene; therefore, we believe that the mecha-
nism of function of the CD4 silencer differs from that ofgene in both CD41 single-positive (SP) and CD81 SP T
cells, indicating that the presence of the factor-binding the RE1/NSRE element.
The mechanism in which the CD4 silencer functionssites removed from the context of the silencer is not
sufficient to mediate CD4 silencer function (pTGSilMin is unknown; however, there are several potential models
that can be drawn from our data. For example, it isconstruct; Figure 7B).
possible that the three sites in the CD4 silencer are
bound either by the same factors or by factors that share
Discussion common chains. Thus, the deletion of one site would
not necessarily lead to the loss of silencer function, as
Functional Redundancy in the CD4 Silencer the presence of the other site(s) would still permit the
We and others identified a transcriptional silencer in the binding of these critical factors. In this model, the factors
first intron of the CD4 gene that is a critical controlling binding sites I, III, or both would share components with
element for proper developmental CD4 gene expression the factor binding site II. Although this is a possibility,
(Siu et al., 1994; Sawada et al., 1994). In this study, it should be noted that there is no significant sequence
we have identified three factor-binding sites in the CD4 similarity between each of the factor-binding sites. A
silencer that are important in silencer function in mature second possibility is that there are three completely
CD81 SP T cells. The CD4 silencer, therefore, shares different factors binding to the three sites, and silencer
structural similarity to the yeast HMR-E silencer, per- function is mediated by the interaction of all three factors
haps the best-characterized eukaryotic transcriptional binding all three sites. In addition, it is interesting to
silencer (Brand et al., 1985; Shore and Nasmyth, 1987). note that site II in the context of the silencer can function
This silencer contains three factor-binding sites for three alone, and yet our biochemical data indicate that the
different nuclear factors (for review see Laurenson and sole factor that binds to this site is present in both
Rine, 1992; Shore, 1995); functional analysis of the CD4 SP and CD8 SP T cells. There are several potential
HMR-E silencer showed that there was significant func- explanations for these data. It is possible that the factor
tional redundancy between these three factors in that binding to site II in the CD8 SP T cell is different than
single deletions of any one of the factor-binding sites the factor binding in CD4 SP T cells, and the similar
did not appreciably affect silencer function. However, migration pattern of the site II-binding complex in these
the deletion of any two of the three sites resulted in two cells is fortuitous. Alternatively, it is possible that
derepression of the yeast mating±type locus. There are either the site II-binding factor is interacting with other
some similarities between the yeast mating±type si- factors binding to the CD4 promoter and enhancer (see
lencer and the CD4 silencer; for example, both contain below), or a coactivator protein is expressed in specific
multiple factor-binding sites that are functionally redun- cell lines to permit such interaction to occur. However,
dant. However, it is important to note that there is a further studies are necessary to address these issues
significant difference in that the redundancy in the CD4 more directly.
silencer is asymmetric: the one factor-binding site can In addition to the neural system silencers mentioned
compensate for the loss of the other two sites. In addi- above, silencer elements have been described for other
tion, we have no evidence to indicate that the factors mammalian genes, including vimentin, lysozyme (Bani-
binding to the CD4 silencer are homologs of the yeast ahmad et al., 1987), collagen II (Savagner et al., 1990),
mating±type silencer; indeed, the CD4 silencer factor- and the TCR a chain (Winoto and Baltimore, 1989). The
binding sites do not show significant sequence similarity CD4 silencer is similar to each of these silencers in that
with the HMR-E silencer factor-binding sites. In addition, it appears to control gene expression in closely related
no mammalian homolog to the RAP-1 yeast silencer- cell types rather than as a major determinant of lineage
binding factor has been identified and it is thus unclear specificity, as with the RE1/NSREelement. Nonetheless,
whether this factor exists in mammals. CD4 silencer function is distinct from all of thepreviously
Another eukaryotic transcriptional silencer that has defined silencer elements in that it alternates between
been characterized is the RE1/NRSE element that is functioning and inactivity at different stages of cell de-
found in silencer elements for the type II voltage-depen- velopment. Thus, the silencer-binding factors we have
dent sodium channel gene and the SCG10 gene (Maue characterized in this work must therefore be functioning
et al., 1990; Mori et al., 1992; Kraner et al., 1992). The at different stages of T cell development. Alternatively,
RE1/NRSE element is a 23 bp sequence that is responsi- different combinations of these silencer-binding factors
ble for silencing these neuron-specific genes in inappro- and coactivators may be functioning at different times
priate cell types. Recently, a factor that binds to this in development to mediate silencer function. To address
site has been cloned (REST/NRSF) and characterized these issues, we are currently characterizing the factors
(Chong et al., 1995; Schoenherr and Anderson, 1995). that bind to these sites further.
This factor is expressed in all cells that do not express Although the three factor-binding sites are critical,
they are not sufficient in and of themselves for silencerthe type II sodium channel gene, and is believed to bind
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function in that a minimal silencer containing just the Our site II biochemistry data are especially intriguing
when considered in conjunction with the functional datafootprinted sites does not silence in our transgenic sys-
tem. There are several possible explanations for our of both the CD4 proximal enhancer and the silencer.
Mutation of the 59 E box in the CD4 enhancer abrogatesdata. First, it is possible that other factors that we have
not detected in our deletion and biochemical data bind both E12-HEB binding and enhancer function in tran-
sient transfection assays. Mutation of the 39 E box abro-within the silencer region. Although this is a possibility,
we consider it less likely, as we could not detect addi- gates the fast mobility complex binding but does not
affect enhancer function (Sawada and Littman, 1993).tional complexes on EMSA other than those identified.
Alternatively, it is possible that the spacing distance As described above, our data indicate that the factor
binding to site II in the silencer may also form the fastbetween the different factor-binding sites is important
for factor interaction. For example, it may be necessary mobility complex by binding to the 39 E box site in the
CD4 enhancer. Although the 39 E box was not consid-for the factor recognition sites to be present at specific
positions on the DNA helix in order for the site-binding ered to be important for enhancing activity, it is possible
that the factorbinding to this site is important for interac-factors to interact. To address this issue, we are cur-
rently generating additional minimal silencer constructs tion with the silencer; previous functional studies on the
CD4 proximal enhancer were conducted using transientthat contain the factor-binding sites at the precise posi-
tion relative to each other as they are in the intact si- transfections and reporter constructs that did not con-
tain the silencer. In addition, these studies were de-lencer. We will then generate transgenic mice with these
constructs to determine whether this synthetic silencer signed to determine the effects of each site mutation
on enhancer function, and thus were assays of enhancercan function properly.
interaction with the promoter; it is possible that the fac-
tor binding to the 39E box may play a different role in CD4The Site II-Binding Factor
Our data indicate that a single complex binds to the site gene expression, such as promoting silencer±enhancer
interaction. Such a model has been proposed for en-II region of the CD4 silencer. Using EMSA analyses, we
have determined that the sole factor binding this site hancer±promoter interactions (Artandi et al., 1994). All
members of the bHLH family bind to their recognitionhas a recognition sequence specificity similar to a bHLH
transcription factor and thus the site II-binding factor sites as dimers; in this model, the binding of the same
factor on both the silencer and the enhancer permitsmay represent a member of this family. Previous studies
have shown that the major transcription factor complex silencer interaction, thus leading to silencing of en-
hancer function. However, additional experiments arethat is responsible for proximal enhancer function is a
heterodimer of an E12-like factor and the HEB transcrip- necessary before we can draw conclusions on mecha-
nisms of silencer±enhancer interaction.tion factor, both of which are members of the bHLH
transcription factor family. Thus, it may be that interac- The identity of the factors binding sites I and III are
unknown. The site I-binding factor has a limited tissuetions between the silencer and the proximal enhancer
are mediated by members of this transcription factor distribution, whereas the site III-binding factor is ex-
pressed in a wide variety of cell types, as demonstratedfamily. Interestingly, the factor that binds to site II has
a sequence specificity similar to a factor binding to the by our EMSA and DNAse footprinting analyses. Despite
the rather broad tissue distributions of these factors,CD4 proximal enhancer, indicating that these factors
may be identical. Although the precise identification of however, our functional data indicate that these factors
can cooperate to convey cell type± and developmentalthis factor is still unknown, we can draw several conclu-
sions from both our data and data presented by Sawada stage±specific silencer function. We have conducted
Southwestern analyses using site III as a probe andand Littman (1993). First, the site II-binding factor dis-
plays exquisite sequence specificity. This factor is capa- have identified a 42 kDa protein complex, which may
represent the site III-binding protein characterizedble of recognizing the site II E box (CAACTG) and the
enhancer 39 E box (CAGCTG), but not the enhancer 59 above (data not shown). We are currently attempting
to clone these transcription factors using a variety ofE box (CAGGTG) (Figures 3B, 4; References). Second,
the site II-binding factor most likely does not contain an different techniques to characterize them further.
E2A or HEB gene product; antisera directed against all
members of this family fail to supershift either the site
A Transgenic Reporter System for StudyingII-binding complex or the fast mobility complex (data not
CD4 Silencer Functionshown; Sawada and Littman, 1993). Third, monoclonal
We have utilized a transgenic reporter system for study-antibodies that cross-react with the bHLH protein ITF-
ing CD4 silencer function. We generated a reporter con-1 also fail to supershift the site II complex, indicating
struct (pTG) that contains all of the transcriptional con-that this factor is also not likely to be ITF-1 (data not
trol elements identified by previous analyses, includingshown). It is possible that this factor is a previously
the distal and proximal enhancers and the promoter.uncharacterized member of these transcription factor
This construct was used as a base construct to test thefamilies, or it may be a member of a different bHLH
effects of the mutated silencer fragments; a total offamily. Recently, a zinc-finger family transcription factor
61 different founder lines were generated and analyzedthat binds to an E box in the immunoglobulin enhancer
from pTG-based constructs. We feel that this systemwas identified (Genettaet al., 1994); thus, it is also possi-
is very useful in the analysis of CD4 silencer function,ble that a factor from this family is binding to site II.
although there are two caveats to our analyses. First,Further characterizations are necessary before defini-
tive conclusions can be drawn, however. as mentioned above, only 50% of the founder lines
Functional Analysis of the CD4 Silencer
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EMSAsestablished with pTG-based constructs express the
EMSA analyses were conducted as described previously (Duncan etmarker gene. This contrasts with our previous datausing
al., 1995). Oligonucleotides encompassing each of the three factor-the l and cosmid constructs; all six of the founders that
binding sites regions were obtained and subcloned into the plasmid
contained intact lB or cosC constructs expressed the vector pKS (Stratagene Cloning Systems, La Jolla, California).
marker gene at high levels (Siu et al., 1994). The lB Probes were generated from these subclones and labeled as de-
scribed (Sambrook et al., 1989). The labeled probe (1.5 3 104 cpm)and cosC constructs contain, in addition to the CD4
was then incubated at room temperature with 1±2 mg of nuclearpromoter and enhancer elements present in the pTG
extract from each cell type plus 0.1±0.5 mg of sheared herring spermconstructs, different combinations of DNAse hypersen-
DNA in 10 mM HEPES KOH (pH 7.9), 50 mM NaCl, 5 mM Tris±HClsitivity sites present in the CD4 locus. It is possible that
(pH 7.5), 25 mM EDTA, 1 mM DTT, and 10% glycerol, either without
when we deleted these additional DH sites we inadver- or with oligonucleotide competitor. After 20 min, the reactions were
tently deleted a transcriptional control region responsi- loaded ontoa 5% nondenaturing polyacrylamide gel and run at 228C
in 13 glycine buffer (190 mM glycine, 25 mM Tris±HCl [pH 8.5], 1ble for permitting high level expression of the CD4 gene,
mM EDTA).such as a locus control region (LCR). Interestingly, there
is a cluster of superhypersensitive DH sites in the far 39
o-Phenanthroline Copper Footprinting Analysisflanking region of the CD4 gene that is present on the
EMSA reactions using D10 nuclear extract and site III probe end-
lB and cosC constructs but not on the lE and pTG labeled on the coding or noncoding strands were scaled up 30-
constructs; the presence of this region on the construct fold and run on 5% nondenaturing polyacrylamide preparative gels.
correlated perfectly with the position-independent ex- Polyacrylamide plugs containing the major site III-binding complex
and the free probe were excised and treated as described (Kuwa-pression of the constructs. We are currently conducting
bara and Sigman, 1987). Plugs were placed in 3 ml 50 mM Tris±HCladditional experiments to characterize this putative
(pH 8.0) and treated at room temperature with 0.3 ml of 20 mMCD4 LCR.
o-phenanthroline, 4.5 mMCuSO4 plus0.3 ml 58 mM mercaptopropri-Another difference that we detected between our re- onic acid. After 10 min, the digestion was terminated with 0.3 ml
vised transgenic system and our previous work was the dimethyl phenanthroline plus 8.1 ml 0.5 M ammonium acetate. Di-
pattern of expression in the thymus. In our previous gestion products were recovered from the polyacrylamide plugs
with overnight elution into buffer followed by isolation over Elutip-Dexperiments, we could detect expression of the marker
columns (Schleicher and Schuell, Keene, New Hampshire). The DNAgene in all CD41 cells, including the immature
was precipitated, resuspended in 80% formamide, 10 mM NaOH, 1CD41CD81 thymocytes (Siu et al., 1994). However, we
mM EDTA, 0.1% bromphenol blue, 0.1% xylene cyanol, and loaded
could not detect marker expression in the CD41CD81 on a 20% sequencing gel.
cells in any of the pTG-based transgenic mice. In addi-
tion, we could not detect marker expression in ten Transgenic Marker Constructs
founder mice transgenic for the pF and pG constructs; Restriction enzyme fragments that contained the CD4 promoter,
enhancers, and silencer were subcloned into the reporter constructthese constructs are similar in construction to pTG in
vector using standard techniques (Sambrook et al., 1989). A 1.3that they contain the minimal promoter and enhancer
kb BglII fragment containing the distal enhancer, a 900 bp BstXIregions and differ only in that they contain small
restriction enzyme fragment containing the proximal enhancer, and
amounts of first intron sequence that do not contain the a 1.0 kb BglII±XhoI fragment containing the CD4 promoter were
silencer (data not shown). To date, we have analyzed cloned into a plasmid containing a cDNA encoding the human MHC
over 71 different pF-, pG-, or pTG-based expressing class I HLA-B7 marker gene and the human b-globin 39 untranslated
region. This construct, referred to as pTG, therefore contains afounders, none of which express the marker gene in the
marker gene under the control of every known CD4 transcriptionaldouble-positive cells. These data strongly imply that
control element except the silencer. The full-length unmutated si-during the construction of these constructs we inadver-
lencer region or deletions of the silencer were then cloned into the
tently deleted a cis-acting transcriptional control ele- unique EcoRV site in the 39 of the marker gene in the sense orienta-
ment important in inducing CD4 expression in double- tion. The pTGSil construct contains the full-length unmutated si-
positive cells. We are currently conducting additional lencer region. pTGSilDI contains the silencer with a 94 bp deletion
from position 1±94 (Figure 1) from the 59 end containing the site Iexperiments to identify this putative enhancer element.
footprint, pTGSilDII contains the silencer with a single 18 bp deletion
from position 172±190 (Figure 1) that encompasses the site II region,
Experimental Procedures and pTGSilDIII contains a 56 bp deletion from position 244±300
containing the site III footprint. The double-deletion (pTGSilDI/II,
pTGSilDI/III, pTGSilDII/III) and triple-deletion (pTGSilDI/II/III) con-In Vitro DNAse Footprinting Analysis
structs are the appropriate combinations of thesingle-site mutationsDNase I footprinting was performed as described previously (Siu et
as described. The minimal silencer construct was generated byal., 1992; Waterman and Jones, 1990). Different restriction enzyme
directly juxtaposing oligonucleotides that contain sites I (75±89), IIfragments encompassing the CD4 silencer region were used to gen-
(172±190), and III (244±300), and cloning the resulting ªsyntheticºerate end-labeled radioactive probes. A mixture of end-labeled si-
silencer into the pTG construct (pTGSilMin). This latter construct,lencer fragment, 1 mg poly(dI±dC), and 10 ml 10% polyvinyl alcohol
however, contains additional sequences between eachof theclonedwas incubated with 40 mg of the appropriate nuclear extracts for
sites from the pKS linker.15 min. A 50 ml volume of 10 mM MgCl2 and 5 mM CaCl2 was added,
followed by DNase I after 1 min more. The reaction was stopped
by adding 90ml 20 mM EDTA, 1% SDS, 0.2 M NaCl, and 325 mg/ml Generation of Transgenic Mice
Transgenic mice were generated using each of the constructs de-carrier RNA, then phenol/chloroform-extracted ethanol was precipi-
tated, and analyzed on a sequencing gel. For these experiments we scribed above using previously published protocols (Hogan et al.,
1986). In brief, construct DNA was excised from the vectors andgenerated extracts from the murine CD41CD82 Th2 cell clone D10,
the murine CD42CD81 cytotoxic T cell clone L3, the murine plas- purified on a 10%±40% continuous sucrose gradient. Fractions con-
taining the appropriate insert DNA were then pooled and dialyzedmacytoma P3X63, the human B cell lymphoma Namalwa, the murine
fibroblast L929, and the human cervical carcinoma line HeLa; the against injection buffer (0.1 mM EDTA, 5 mM Tris±HCl [pH 7.5]). The
DNA was then sterile filtered and microinjected into the pronucleicell lines were maintained and the extracts purified as described
previously (Siu et al., 1992; Duncan et al., 1995). of fertilized mouse eggs obtained from (C57BL/6 3 DBA)F1 3
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(C57BL/6 3 DBA)F1 crosses. The injected eggs were then implanted C., and Mathis., D. (1991). Mice lacking MHC class II molecules.
Cell 66, 1051±1066.into Swiss±Webster foster mothers as described previously. Found-
ers were identified using a combination of polymerase chain reaction Duncan, D.D., Stupakoff, A., Hedrick, S.M., Marcu, K.B., and Siu,
techniques and flow cytometric analysis on peripheral blood. We G. (1995). A Myc-associated zinc-finger protein (MAZ) binding site
injected and implanted a total of 1,930 eggs into 81 pseudopregnant is one of four important functional regions in the CD4 promoter.
mothers; 63 of which became pregnant and gave birth to a total of Mol. Cell. Biol. 15, 3179±3186.
250 babies, of which 61 were transgenic (incorporation rate of
Fowlkes, B.J., and Pardoll, D. (1989). Molecular and cellular events
24.4%). To insure that the inserted transgenic construct in each
of T cell development. Adv. Immunol. 44, 207±264.
founder was correct, the mutantsilencers wereresequenced directly
Genetta, T., Ruezinsky, D., and Kadesch, T. (1994). Displacementfrom the transgenic mice using cycle sequencing (data not shown).
of an E-box-binding repressor by basic helix±loop±helix proteins:Multiple expressing founders were analyzed for each construct; the
implications for B-cell specificity of the immunoglobulin heavy-chainresults from one representative founder for each construct are
enhancer. Mol. Cell. Biol. 14, 6153±6163.shown. All other founders were consistent with those shown (data
Grusby, M.J., Johnson, R.S., Papaionnou, V.E., and Glimcher., L.H.not shown).
(1991). Depletion of CD41 T cells in majorhistocompatibility complex
class II±deficient mice. Science 253, 1417±1420.Flow Cytometric Analysis
All analyses were performed on 4- to 7-week-old littermates housed Hogan, B., Costantini, F., and Lacy, E. (1986). Manipulating the
in a pathogen-free facility at Columbia University. The following Mouse Embryo: A Laboratory Manual (Cold Spring Harbor, New
antibodies were used to stain splenic T cells: fluorescein isothiocya- York: Cold Spring Harbor Laboratory Press).
nate±conjugated GK1.5 (CD4), allophycocyanin-conjugated 53-6.7
Kaye, J., Hsu, M.-L., Sauron, M.E., Jameson, S.C., Gascoigne,
(CD8), and either ME1 (mouse immunoglobulin G1 [IgG1] anti-HLA-
N.R.J., and Hedrick, S.M. (1989). Selective development of CD41 T
B7; Chamberlain et al., 1988) or MOPC-31c (mouse IgG1 isotype
cells in transgenic mice expressing a class II MHC-restricted antigen
control) followed by phycoerythrin-conjugated goat anti-mouse
receptor. Nature 341, 746±749.
IgG1 (Caltag). Forward and orthogonal light scatter were used to
Kisielow, P., Bluthmann, H., Staerz, U.D., Steinmetz, M., and vongate on the lymphocyte populations. Dead cells were excluded from
Boehmer, H. (1988a). Tolerance in T cell±receptor transgenic miceanalysis using propidium iodide. All cell populations were analyzed
involves deletion of nonmature CD4181 thymocytes. Nature 333,on a FACStar Plus flow cytometer (Becton Dickenson) at the Flow
742±746.Cytometry Facility at the Cancer Center of Columbia University.
Kisielow, P., Teh, H.S., Bluthmann, H., and von Boehmer, H. (1988b).
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